Navigation Links
AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
Date:11/30/2007

WILMINGTON, Del., Nov. 30 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it has completed enrollment of patients in the ZEST (ZACTIMA Efficacy Study versus Tarceva) study, the first of four Phase III trials for the investigational once-daily oral anti-cancer drug vandetanib. Data from the study is expected in 2008.

ZEST is a randomized, double-blind, multi-center Phase III study to assess the efficacy of vandetanib versus erlotinib in overall survival (OS) and progression-free survival (PFS) in over 1,150 patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) after failure of first-line anti-cancer therapy.

"Non-small cell lung cancer is an area of high unmet medical need, and we hope vandetanib will offer a beneficial new treatment option for people with lung cancer," said Dr. Peter Langmuir, Medical Science Director at AstraZeneca.

ZEST is part of a Phase III clinical trial program to gain a broad understanding of how vandetanib may benefit people with lung cancer.

The other studies are:

-- ZODIAC (vandetanib + docetaxel versus docetaxel alone)

-- ZEAL (vandetanib + pemetrexed versus placebo + pemetrexed); and,

-- ZEPHYR (vandetanib + best supportive care (BSC) versus placebo + BSC).

These studies are currently recruiting patients.

The Phase III program in NSCLC follows results from two Phase II trials where vandetanib was studied either alone or in combination with standard chemotherapy (docetaxel). (1)(2) Vandetanib is also being evaluated as a treatment option in medullary thyroid cancer and has been awarded Food and Drug Administration (FDA) orphan drug status and fast track designation for this indication.

About AstraZeneca

AstraZeneca is a major international health care business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of health care services. It is one o
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento) today announced ... Officer and Executive Vice President. Mr. Singh died suddenly and ... "Sorrento is deeply saddened and shocked by the loss of ... Amar,s family and friends," said Henry Ji , Ph.D., ... Singh joined Sorrento in January 2014 from Synta Pharmaceuticals, where ...
(Date:7/31/2014)... July 31, 2014  ResMed Inc. (NYSE: RMD ... the fiscal year ended June 30, 2014.  Revenue for the ... June 30, 2013 (a 1 percent decrease on a constant ... 20 percent compared to the quarter ended June 30, 2013. ... increase of 22 percent compared to the quarter ended June ...
(Date:7/31/2014)... 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... the quarter ended June 30, 2014. Financial Results ... Revenue Total revenue for the quarter ended June 30, ... quarter ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23
... AT&T * today announced that the Arkansas Department ... mobile flu clinic solution to help the agency more efficiently ... to extend the use of the application to other year-round ... As an important part of its mission to ...
... 2011 Inhibitex, Inc. (Nasdaq: INHX ) today ... shares of its common stock, at a purchase price of ... The net proceeds to Inhibitex from the sale of the ... are expected to be approximately $44 million.  Inhibitex has granted ...
Cached Medicine Technology:Arkansas Department of Health Chooses AT&T to Streamline Delivery of Public Health Programs 2Arkansas Department of Health Chooses AT&T to Streamline Delivery of Public Health Programs 3Arkansas Department of Health Chooses AT&T to Streamline Delivery of Public Health Programs 4Inhibitex Prices $47 Million Public Offering 2Inhibitex Prices $47 Million Public Offering 3
(Date:8/2/2014)... (PRWEB) August 02, 2014 Apervi, ... orchestration platform simplifying data engineering for big data, ... is one of the first Enterprise data engineering ... Spark. Databricks, the company founded by the creators ... as a means to encourage new development on ...
(Date:8/2/2014)... (PRWEB) August 02, 2014 CEDR ... nation's number one provider of customized medical and dental ... major dental-industry conferences this fall. CEDR’s CEO will be ... September and early December. , From September 4-6, CEDR ... Office Managers (AADOM) Dental Managers Conference in San Diego, ...
(Date:8/1/2014)... Recently, iFitDress.com, one of the most famous dress suppliers ... top bridesmaid dresses online. At the moment, all the ... 52% off. According to the company’s senior spokesman, the special ... The company’s stock is limited. Those who are thinking of ... soon as possible. All its products are delicately made by ...
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
(Date:8/1/2014)... 2014 Stryker hip lawsuits ( ... 2012 Rejuvenate and ABG II Modular-Neck Hip Stem ... Bergen County Superior Court, Bernstein Liebhard LLP reports. ... Court has issued a Final Amended Stipulated ... hard copy and electronic materials produced by any ...
Breaking Medicine News(10 mins):Health News:Databricks Certifies Apervi Conflux Director TM on Spark, Supercharging the Data to Insight Journey 2Health News:Databricks Certifies Apervi Conflux Director TM on Spark, Supercharging the Data to Insight Journey 3Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 2Health News:Nuanced Media Client, CEDR HR Solutions, to Speak at Upcoming Major Dental Conferences 3Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3
... inflammation and loss of cartilage in joints, is likely ... // ,Researchers led by David Felson, a professor ... with symptomatic osteoarthritis of the knee for 30 months. ... the online edition of BBC News. ,The ...
... for capacity Building', Ministry of Health and Family ... Rs. 1.50 crores or actual, whichever is less, ... State Hospitals of towns/cities located on National Highways. ... Road Transport and Highways and Ministry of Health ...
... an amazing figure at the cost of their own health. ... large population is opting for laxative abuse. ,Assumptions about ... which proved that 20% of women who wanted to lose ... students. ,Though these women start with few pills a ...
... 9th of November, urging parents to prevent use of fluoridated ... dentists are concerned about the exposure to fluoride at such ... teeth it might permanently damage them, apart from which it ... cancer boys. ,This advice is not noticed by many ...
... of food poison. Then, fame came as a temporary ... 'miracle poison' and used for an increasing number of ... Mayo Clinic Health Letter covers how this drug works ... ,Botulinum toxin blocks communication between nerves and muscles. Food ...
... the increasing number of children pronounced as juvenile diabetics, it ... such diseases //on their little ones. What used to ... silently attacking children, and it is imperative that parents and ... hand. ,New data from the International Diabetes ...
Cached Medicine News:Health News:Laxatives are Not the Right Option for Losing Weight 2
Stainless steel bone clamp....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
To elevate, dissect, scrape and apply traction to bone and soft tissue....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Medicine Products: